Abstract

It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.
Original languageEnglish
Pages (from-to)699-701
Number of pages3
JournalRheumatology
Volume59
Issue number4
Early online date9 Nov 2019
DOIs
Publication statusPublished - 1 Apr 2020

Bibliographical note

The authors would like to thank Dr Mohammad Derakhshan, BRITSpA Research Fellow (2016–2019) and Karly Graham, administrator. H.M.O. is supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health.

Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

Fingerprint

Dive into the research topics of 'BRITSpA at five'. Together they form a unique fingerprint.

Cite this